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Abstract 
Three new mixed-chelate copper complexes with 3-aminoquinoxaline-2-carbonitrile N1,N4-
dioxide derivatives and alanine as ligands were synthesized in solid state. The spectroscopic 
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characterization (FTIR, EPR, UV-Vis) showed that copper coordinated through the amine and the 
N-oxide groups of the quinoxaline derivatives and the amine and carboxylate moieties from alanine 
forming a dimeric species. The tree complexes showed in vitro activity against M. tuberculosis 
H37Rv (ATCC 27294) similar to that of ethambutol while they are inactive against E. coli and S. 
aureus. 
Keywords: antimycobacterial agents, copper complexes, quinoxaline derivatives. 
 
Resumen 
Tres nuevos complejos mixtos de cobre con derivados de 3-aminoquinoxalina-2-
carbonitrilo N1,N4-dióxido y alanina como ligandos fueron sintetizados en estado sólido. La 
caracterización espectroscópica (FTIR, EPR, UV-Vis) mostró que el Cu coordina con el 
grupo amino y el N-óxido del derivado quinoxalínico y con el amino y el carboxilato de la 
alanina formando especies diméricas. Los tres complejos mostraron actividad frente al M. 
tuberculosis H37Rv (ATCC 27294) similar a la del etambutol, mientras que fueron inactivos frente a 
E. coli y S. aureus. 
Palabras clave: agentes antimicobacterianos, complejos de Cu, derivados quinoxalínicos. 
 
 
Introduction 
Tuberculosis is an infectious disease caused by mycobacteria, mainly Mycobacterium 
tuberculosis. It can lead to serious complications and even death, especially if it is accompanied by 
other bacterial infections and if the patients have their immune systems compromised by 
immunosuppressive drugs, abuse substances, or HIV/AIDS, among others [1]. 
The World Health Organization (WHO) estimates that about 30 million people will be 
infected in the next 20 years, not only in the third world but also in the developed countries [1]. In 
view of the importance of this disease and the emergence of multi-drug resistant strains, the 
investigation and development of new drugs is a leading area of research.  
The study of quinoxaline derivatives has become of much interest in recent years due to 
their antibacterial, antiviral, anticancer, antifungal, antihelminthes and insecticidal activities [2]. In 
particular, the di-N-oxide derivatives of quinoxaline show a dramatically increase of the diversity of 
biological properties. For example, some of these organic derivatives have shown hypoxia-selective 
citotoxicity and they could be potentially useful for the treatment of solid tumors. Besides, some 
derivatives have presented excellent M. tuberculosis growth inhibition values, leading generally the 
lack of the two N-oxide groups to the loss of the antimycobacterial activity [3-6]. Although 
excellent in vitro biological results have been obtained with some 3-amino-2-carbonitrile-
quinoxaline N1,N4-dioxide derivatives, they were not useful for therapy owing to too short in vivo 
half lives and low solubility in physiological media [7-10]. 
As an effort to improve bioavailability and pharmacological and toxicological properties of 
quinoxaline N1,N4-dioxide derivatives, we have focused our current research on the synthesis, 
characterization and biological evaluation of a large amount of metal complexes with this family of 
organic compounds [11-15]. These studies lead to several complexes with higher pharmacological 
activity than the free ligands, especially iron complexes bearing anti-Mycobacterium tuberculosis 
activity. Nevertheless, in many cases the lipophilicity and solubility of the developed complexes 
still remained non adequate for therapeutically purposes. Therefore we decided to take advantage of 
a well known strategy in the search for more active metal-based drugs that involves the 
incorporation of a second ligand in the metal coordination sphere, like an aminoacid, with the aim 
of obtaining different levels of hydrophobicity [16]. Taking into account these antecedents and 
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trying to know more about the effect of metal coordination on the bioactivity of selected 3-
aminoquinoxaline-2-carbonitrile N1,N4-dioxide derivatives, in this work we present the synthesis in 
solid state and the analytical and spectroscopic characterization of a new series of mixed-chelate 
Cu(II) complexes with different non- and mono-substituted 3-aminoquinoxaline-2-carbonitrile 
N1,N4-dioxide derivatives (Figure 1) and alanine (ala) as ligands. Besides, their antibacterial 
activities against E. coli, S. aureus and M. tuberculosis are reported.  
 
Experimental 
Materials and methods 
All starting materials were commercially available research-grade chemicals and were used 
without further purification. The quinoxaline derivatives (see Figure 1) were synthesized in CIFA, 
Navarra University, Pamplona (Spain) by Dr. Monge’s group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
N+
N+R1
R2
O-
O-
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Figure 1. 3-aminoquinoxaline-2-carbonitrile N1,N4-dioxides used as ligands. 
 
 
 
Synthesis of the complexes 
The complexes were synthesized through a solid state technique [17] by mixing 
CuCO3Cu(OH)2 (11 mg), alanine (9 mg) and L (20.0 mg of L1 or 23.5 mg of L2 or 22.0 mg of L3), 
adding some drops of water and heating the mixture at 80 ºC during 6 h. In all the cases red 
complexes were formed. The yields (%) were 95.5, 77.6 and 90.0, respectively.  
The stoichiometries obtained were [Cu(L-H)(ala-H)] for the three complexes where L-H and 
ala-H are the deprotonated ligands. 
The results of the elemental analysis (%) obtained with a Carlo Erba EA 1108 analyzer 
were: for [Cu(L1-H)(ala-H)] (Code CuL1ala) C12H12N5O4Cu Found/ Calc.: C, 40.48/ 40.97; N, 
19.74/ 19.91; H, 3.05/ 3.15; for [Cu(L2-H)(ala-H)] (Code CuL2ala) C12H11N5O4ClCu Found/ Calc.: 
C, 36.89/ 37.06; N, 17.58/ 18.02; H, 3.02/2.83 and for [Cu(L3-H)(ala-H)] (Code CuL3ala) 
C12H11N5O4FCu Found/ Calc.: C, 38.72/ 38,76; N, 18.61/ 18.84; H, 3.15/ 2.96. 
The electronic spectra of the three complexes showed in DMF and ethanol a broad band near 
500 and a shoulder near 570 nm, in agreement with the red-purple colour of the solutions.  
 
 
 
    Ligand R1 R2  
L1 H H  
L2 Cl H  
L3 F H  
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Spectroscopic measurements  
IR spectra, in the range between 4000 and 400 cm-1, were recorded on a Bomem M 102 
FTIR spectrophotometer using the KBr pellet technique. Electronic spectra of the complexes were 
registered on a Shimadzu UV-1603 spectrophotometer. 
Electron Paramagnetic Resonance (EPR) experiments were carried out in a Bruker 
ELEXSYS E580 spectrometer operating at 9.5 GHz. EPR spectra of solid- (polycrystalline) and in 
DMSO solution samples of the three compounds were measured at 30 K using experimental 
parameters such that signal saturation and distortion was avoided. Temperature was controlled by 
means of an ITC503 Oxford cryostat system. 
 
Microbiological assays 
Agar dilution tests were used to determine the minimal concentration of the antimicrobial 
agent required to inhibit or kill the microorganisms (MIC). Every step in the procedure for 
performing the agar dilution susceptibility test [18] was based on recommendations from the 
National Committee for Clinical Laboratory Standards [19].  
A suspension in sterile physiological serum of the complexes was incorporated in 20 mL of 
Mueller-Hinton agar and poured into Petri dishes. The pH of each batch of medium was in the range 
7.2 to 7.4. The dilution scheme for each antimicrobial agent covered a 400-12.5 μg of complex/mL 
range. The same process was carried out with a water dilution of CuSO4·5H2O. 
 The standard strains used were E. coli ATCC 25922 and S. aureus ATCC 29213. In each 
case, a suspension of about 104 colony-forming units / drop (CFU/drop) in Trypticase soy broth was 
prepared and diluted (1:20) in physiological serum. One drop of this suspension was inoculated on 
the agar surface containing the indicated dilutions of the antimicrobial agent, and on the control dish 
containing no antimicrobial agent. 
All tests and inoculations on each dish were run in duplicate.   
The anti-M. tuberculosis activities of the compounds were determined using the MABA as 
analytical method [20]. Stock solutions of copper complexes were prepared in dimethyl sulfoxide 
and diluted in broth medium Middlebrook 7H9 (Difco), supplemented with oleic acid, albumin, 
dextrose, and catalase (OADC enrichment - BBL/Becton-Dikinson, Sparks, MD, USA), to obtain 
final compounds concentration ranges of 0.15 to 50 μg/mL. Isoniazid was solubilized with distilled 
water according to the manufacturers’ recommendations (Difco laboratories, Detroit, MI, USA) and 
used as standard drug. M. tuberculosis H37Rv ATCC 27294 was grown for 7 to 10 days in 
Middlebrook 7H9 supplemented with OADC added of 0.05 % Tween 80 to avoid clumps. 
Suspensions were prepared and their turbidities matched to a McFarland no. 1 (turbidity standard). 
After further dilution of 1:25 in Middlebrook 7H9 supplemented with OADC, the inoculum was 
added to each well of the 96 well microtiter plate (Falcon 3072; Becton Dickinson, Lincoln Park, 
NJ) together with the compounds. Samples were set up in triplicate. Cultures were incubated for 7 
days at 37 oC, and Alamar Blue was added for the reading. The minimum inhibitory concentration 
(MIC) was defined as the lowest concentration resulting in 90 % inhibition of growth of M. 
tuberculosis determined by measuring the fluorescence (excitation/emission of 530/590 nm filters 
respectively) in a SPECTRAfluor Plus (Tecan) instrument. For standard test, the MIC value of 
isoniazid was determined each time. The acceptable MIC of isoniazid ranged from 0.015 to 0.05 
µg/mL [21]. 
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Results and discussion 
Infrared spectra 
The IR spectra of the complexes were compared with those of the free ligands and of 
previously reported complexes [11-15] [22] [23]. The results obtained are shown in Table 1. For the 
sake of clarity data of alanine IR spectrum were also presented in Table 1. Figure 2 shows as an 
example the IR spectra of L3, ala and the corresponding complex. 
All the complexes showed a similar spectral pattern. After the coordination the ligand´s 
bands corresponding to νas(NH2) (in the 3336-3436 cm-1 range) and νs(NH2) (in  the 3255-3295 cm-
1 range) of the amino group of quinoxaline derivatives disappeared and only one band was observed 
(in the 3298-3385 cm-1 range). This is in accordance with the presence of a secondary amine formed 
by deprotonation of the primary amine as a consequence of the coordination with copper ion, as 
previously observed for vanadyl and copper complexes with this family of ligands. This behavior 
was also observed in metal chelates with aromatic ligands involving the amino group in ortho 
position to the N-oxide [11-15] [22]. 
 
 
 
Table 1. Main bands and proposed assignments (cm-1) of copper complexes IR spectra and free 
ligands 
 
Compound νas(NH2) νs(NH2) ν(NH) ν(N-O) νas(C≡N) δ(NH3+) νas(COO-) νs(COO-) 
L1 3353 3262 - 1343 2237 - - - 
CuL1ala -* -* 3385 - 2226 - nd 1395 
L2 3436 3295 - 1335 2237 - - - 
CuL2ala -* -* 3298 - 2221 - nd 1389 
L3 3336 3255 - 1345 2231 - - - 
CuL3ala -* -* 3373 - 2229 - nd 1397 
ala 3082 2991-2936 - - - 2113 1590 1413 
*:Only the symmetric and antisymmetric stretchings of the quinoxaline ligands were included ; nd = not 
determined. 
 
 
Furthermore, the strong ν(N→O) band for the free ligands (1335-1345 cm-1) shifted in the 
complexes being overlapped with other bands, showing the coordination through this group. The 
ν(C≡N) (2221-2237 cm-1) suffered only minor changes upon complexation in agreement with the 
fact that this group did not coordinate to copper ion. 
Moreover, data show the copper coordination through the alanine ligand in the three 
complexes. The free aminoacid exists as zwitterion in the crystalline state. This is demonstrated by 
the existence of the δ(NH3+) band at 2113 cm-1. This band disappeared in the complexes showing 
the copper coordination through the amine terminal group of the alanine ligand. Besides, two 
vibrations for the COO- moiety (νas(COO- ) at 1590 cm-1 and  νs(COO- ) at 1413 cm-1 ) are observed 
in the zwitterion. After coordination a lowering of the frequency of one of these bands and the 
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increase of the other are expected. In our complexes, νs(COO-) shifted to low frequencies (1389-
1397 cm-1). This behavior is similar to that of [Cu(ala)2] that presents one band at 1400 cm-1 [23]. 
The νas(COO-) was overlapped by quinoxaline bands and consequently could not be assigned.  
Besides, the strong band assigned as νas(NH2) in the alanine spectrum (3082 cm-1) shifted to 
higher wavelengths in the mixed-chelate complexes (around 3244 cm-1). This behavior is in 
agreement with previously reported data for [Cu(ala)2] (3245 cm-1) [23-24]. 
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Figure 2. IR spectra of ligands (quinoxaline derivative and ala) and the corresponding complex 
CuL3ala 
 
 
EPR spectra 
Polycrystalline samples of the three complexes presented EPR spectra (Figure 3) 
characteristic of coupled pairs with a distorted resonance around 330 mT (g~2) and a half-field 
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transition around 165 mT (inset in Figure 3A). This half-field line is only observed in S=1 spin 
systems and is the result of the “forbidden” ΔMS=±2 transition [25]. Hence, in the solid state, the 
complexes exist as dimmers containing exchange-coupled pairs of S=1/2 Cu(II) ions as previously 
observed for other copper compounds in the same conditions [12, 13, 26]. Upon dilution in DMSO, 
the spectra change to the usual EPR spectra of Cu(II) ions (Figure 3B) showing features assigned to 
the hyperfine interaction between the S=1/2 electron spin and the I=3/2 nuclear spin [27, 28]. The 
frozen-solution spectra are characterized by the following parameters: g//=2.2513, A//=17.5 mT, 
g⊥=2.0590. Our EPR results thus show that, in solution, the complexes are in a tetragonally 
monomeric form with ground state dx2-y2. The EPR spectrum at room temperature shows the same 
behavior (data not shown). 
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Figure 3. Low-temperature (30 K) EPR spectra from: (A) polycrystalline samples and (B) 
DMSO solutions of CuL1ala, CuL2ala, and CuL3ala. The inset shows the half-field 
transition discussed in the text. 
 
 
 
Microbiological assays 
The minimum inhibitory concentration (MIC) values of Cu complexes against E.coli (ATCC 
25922), S. aureus (ATCC 29213) and M. tuberculosis H37Rv (ATCC 27294) are shown in Table 2.  
The three complexes were inactive against E.coli and S. aureus, while they were active 
against M. tuberculosis. The MIC values of all the complexes are of the same order than that of 
ethambutol (MIC = 5.62 μg/mL), an antimycobacterial agent in clinical use. Nevertheless, they are 
less active than other drugs like p-amino salicylic (PAS) (MIC = 1.25 μg/mL) and isoniazid (MIC = 
0.03-0.015μg/mL). 
Taking into account the analytical and spectroscopic results and our antecedents with Cu 
complexes of this kind of ligands, a possible structure for the complexes is proposed in Figure 4. 
This proposal is supported by our previous studies where homoleptic copper-quinoxaline complexes 
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[12-13] showed the presence of bridges that permitted to explain the dimeric molecules shown by 
EPR. Besides, a similar IR pattern was observed by the compounds presented in this work. 
 
 
Table 2. MIC values (μg/mL) of Cu complexes against E. coli, S. aureus and M. tuberculosis 
Compound E. coli S. aureus M. tuberculosis 
CuL1ala > 400 > 400 7.8 
CuL2ala > 400 > 400 7.8 
CuL3ala >400 > 400 7.8 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Scheme of the proposed structure for the copper 
complexes (R=-CH3). 
 
 
Conclusions 
Three new mixed-chelate copper complexes with 3-aminoquinoxaline-2-carbonitrile N1,N4-
dioxide derivatives as ligands were synthesized in solid state. The spectroscopic characterization 
showed that copper coordinated with both ligands: quinoxaline derivative and alanine, forming 
dimeric species in the solid state. The three complexes showed in vitro activity against M. 
tuberculosis H37Rv (ATCC 27294) similar to that of ethambutol. These results have encouraged us 
to continue this research further. 
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